HPV vaccine safe for HIV+ girls and women: CTN 236
The safety and potential efficacy of vaccination against the human papillomavirus (HPV) in HIV-positive women...
Learn MoreThe safety and potential efficacy of vaccination against the human papillomavirus (HPV) in HIV-positive women...
Learn MoreFebruary saw a possible turning point in the prevention of HIV, when Health Canada approved Truvada...
Learn More“Young guys today didn’t live through the AIDS crisis,” says CTN postdoc Nathan Lachowsky in...
Learn MoreThe REPRIEVE trial (A5332, CTN 293 – Randomized Trial to Prevent Vascular Events in HIV)...
Learn MoreHIV can be transmitted through breast milk, yet the risk of transmission is not well...
Learn MoreTreatment access issues related to hepatitis C virus (HCV) infection and HIV-HCV co-infection dominated much...
Learn MoreOn Friday, July 17 and Saturday, July 18 the 2nd International HIV/Viral Hepatitis Co-Infection Meeting brought together...
Learn MoreIn 1993 the formation of a community advisory committee was groundbreaking. Over the past 25...
Learn MoreFor the last 25 years the CTN has played a central role in driving Canada’s...
Learn MoreThe results of Phase I of the ANRS IPERGAY trial (CTN 268) are very promising,...
Learn MoreThe TriiAdd study (CTN 286) will test to see if using a new single tablet...
Learn More